Wells Fargo & Company Silence Therapeutics PLC Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Wells Fargo & Company holds 19 shares of SLN stock, worth $77. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19
Previous 19
-0.0%
Holding current value
$77
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLN
# of Institutions
66Shares Held
24.6MCall Options Held
500Put Options Held
5K-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$12.3 Million3.41% of portfolio
-
Siren, L.L.C. New York, NY2.83MShares$11.5 Million0.86% of portfolio
-
Redmile Group, LLC San Francisco, CA2.4MShares$9.74 Million1.29% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.86MShares$7.54 Million1.01% of portfolio
-
Morgan Stanley New York, NY1.66MShares$6.75 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $146M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...